MLYS
Price
$9.56
Change
+$0.03 (+0.31%)
Updated
Feb 21 closing price
Capitalization
476.43M
85 days until earnings call
RANI
Price
$1.66
Change
-$0.07 (-4.05%)
Updated
Feb 21 closing price
Capitalization
55.3M
24 days until earnings call
Ad is loading...

MLYS vs RANI

Header iconMLYS vs RANI Comparison
Open Charts MLYS vs RANIBanner chart's image
Mineralys Therapeutics
Price$9.56
Change+$0.03 (+0.31%)
Volume$335.44K
Capitalization476.43M
Rani Therapeutics Holdings
Price$1.66
Change-$0.07 (-4.05%)
Volume$227.81K
Capitalization55.3M
MLYS vs RANI Comparison Chart
Loading...
MLYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RANI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MLYS vs. RANI commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLYS is a Hold and RANI is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (MLYS: $9.56 vs. RANI: $1.66)
Brand notoriety: MLYS and RANI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MLYS: 121% vs. RANI: 18%
Market capitalization -- MLYS: $476.43M vs. RANI: $55.3M
MLYS [@Biotechnology] is valued at $476.43M. RANI’s [@Biotechnology] market capitalization is $55.3M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.51B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MLYS’s FA Score shows that 0 FA rating(s) are green whileRANI’s FA Score has 0 green FA rating(s).

  • MLYS’s FA Score: 0 green, 5 red.
  • RANI’s FA Score: 0 green, 5 red.
According to our system of comparison, MLYS is a better buy in the long-term than RANI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MLYS’s TA Score shows that 6 TA indicator(s) are bullish while RANI’s TA Score has 5 bullish TA indicator(s).

  • MLYS’s TA Score: 6 bullish, 3 bearish.
  • RANI’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, MLYS is a better buy in the short-term than RANI.

Price Growth

MLYS (@Biotechnology) experienced а -6.64% price change this week, while RANI (@Biotechnology) price change was -10.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

MLYS is expected to report earnings on May 19, 2025.

RANI is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MLYS($476M) has a higher market cap than RANI($55.3M). RANI YTD gains are higher at: 21.168 vs. MLYS (-22.340). RANI has higher annual earnings (EBITDA): -48.72M vs. MLYS (-168.35M). MLYS has more cash in the bank: 264M vs. RANI (30.4M). MLYS (0) and RANI (0) have equivalent revenues.
MLYSRANIMLYS / RANI
Capitalization476M55.3M861%
EBITDA-168.35M-48.72M346%
Gain YTD-22.34021.168-106%
P/E RatioN/AN/A-
Revenue00-
Total Cash264M30.4M868%
Total DebtN/A33.7M-
TECHNICAL ANALYSIS
Technical Analysis
MLYSRANI
RSI
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 3 days ago
73%
Bullish Trend 3 days ago
89%
MACD
ODDS (%)
Bullish Trend 3 days ago
79%
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 10 days ago
85%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
87%
Aroon
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
71%
View a ticker or compare two or three
Ad is loading...
MLYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RANI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HDRVX16.63-0.04
-0.24%
Janus Henderson Responsible Intl DivN
VCGAX34.64-0.62
-1.76%
VALIC Company I Systematic Core Fund
FSSKX80.14-1.61
-1.97%
Fidelity Stock Selec-Class K
EMCAX64.07-1.85
-2.81%
Empiric Class A
HCMIX29.55-1.08
-3.53%
HCM Tactical Growth I

MLYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLYS has been loosely correlated with ABOS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MLYS jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLYS
1D Price
Change %
MLYS100%
+0.31%
ABOS - MLYS
45%
Loosely correlated
+0.72%
IDYA - MLYS
40%
Loosely correlated
+0.55%
CELC - MLYS
40%
Loosely correlated
+0.15%
RCKT - MLYS
40%
Loosely correlated
-3.68%
ERAS - MLYS
39%
Loosely correlated
-3.42%
More

RANI and

Correlation & Price change

A.I.dvisor tells us that RANI and DRUG have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RANI and DRUG's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RANI
1D Price
Change %
RANI100%
-4.05%
DRUG - RANI
31%
Poorly correlated
-0.44%
UBX - RANI
31%
Poorly correlated
-5.37%
FATE - RANI
28%
Poorly correlated
-8.09%
BLUE - RANI
27%
Poorly correlated
-42.05%
MLYS - RANI
26%
Poorly correlated
+0.31%
More